Back to results
US 2026/0028342 A1Published application
Enhancing antimetastasis activity using targeted protein degradation
OwnerKevin Frankowski, Feijun Wang +2inventors
InventorsKevin Frankowski, Feijun Wang, Sui Huang, Emma Freeman
Life of this patent
Estimating the term…
Abstract
The current invention relates to transcription elongation factor eEF1A2-targeted protein degradation ligands and pharmaceutical compositions thereof and their utility as anti-cancer agents.
Claims33
A compound of Formula (I):
- or an enantiomer, diastereomer, an enantiomeric mixture, a diastereomeric mixture or a pharmaceutically acceptable salt thereof;
- wherein:
- A is selected from
- L is selected from
- wherein a, b, c, d, e, n, m, p, q, r, s, t, u, v, w, y and z are an integer independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and X is selected from —CH2—, —NH—, and —O—;
- and
- E is selected from
4 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound of formula (IV):
- or an enantiomer, diastereomer, an enantiomeric mixture, a diastereomeric mixture or a pharmaceutically acceptable salt thereof;
- wherein:
- L is selected from
- wherein a, b, c, d, e, f, g, h, i, j, and k are an integer independently selected from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and X is selected from a bond —CH2—, —NH—, and —O—, and
- E is selected from
2 more elements
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.